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Introduction: Demographic factors, symptom severity, and psychopathology, in particular
anxiety and depression, are known to influence health care use and quality of life in
asthma. Because depression and anxiety are typically correlated, we sought to explore
whether depression specifically is associated with health care utilization and quality of life
when effects of anxiety are controlled for.
Method: In a cross-sectional questionnaire study, 88 asthma patients (46 women; age
range 27–70 years) reported on symptoms and treatment of their disease, as well as
anxiety and depression (Hospital Anxiety and Depression Scale, HADS), general quality of
life (Short Form 12 Health Survey Questionnaire, SF-12) and asthmatic-specific quality of
life (Living with Asthma, LAQ).
Results: While no considerable associations between anxiety and health care use were
found, the associations between higher scores in depression and hospital visits as well as
days of corticosteroid intake were significant. Furthermore, considerable variance in all
subscales of quality of life questionnaires was explained by higher scores in depression,
even when controlling for anxiety. For anxiety scores these associations were comparable,
except for physical well-being.
Conclusion: Depression is an important issue in asthma, as it is substantially related to
quality of life and intake of corticosteroids, and marginally to hospitalization. Routine
screening for depression should be considered in hospital and primary care.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Patients with chronic diseases are in general more at risk for
mental disorder.1 In asthma, anxiety and depression are the
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example, Feldman et al.2 found in a sample of 85 adult
asthma patients that 65% had any psychiatric disorder,
and criteria for mood disorders and anxiety disorders were
met by 51% and 45% of their sample, respectively. In
general, numerous researchers have found in patients
with asthma elevated levels of anxiety disorders,3,4 in
particular panic disorder, and depression.5 Mrazek6 hypothe-
sized that the stress of having a chronic illness increases the
likelihood of the development of anxiety and depression
symptoms.
Chronic disease patients with an additional psychiatric
disorder such as depression typically utilize health care
services more often compared to chronic disease patients
without additional psychiatric disorders.7 Ten Brinke et al.8
found that patients with both severe bronchial asthma and a
psychiatric disorder visit their GP more often than asth-
matics without a psychiatric disorder and require frequent
emergency and hospital admissions. In asthma, anxiety and
panic are particularly relevant due to their role in
interfering with the management of asthma attacks.
Furthermore, asthma patients with strong panic-fear
during an asthma attack visit their GP more often9 and
have longer periods of hospitalization and a higher rate of
rehospitalization than asthmatics without such psycho-
pathological symptoms.10 These authors and subsequently
others also observed a positive association between panic-
fear and prescriptions or intake of oral corticosteroids,11,12
with Bonala et al.13 reporting a positive correlation bet-
ween both increased anxiety and depression and higher
dosing of corticosteroids in asthmatics. Specifically with
depression, it has been reported that children as well as
older adults with asthma and depressive symptoms have
higher levels of hospitalization than asthmatics without
depressive symptoms.14,15 However, relatively fewer find-
ings in this field of research have been published regarding
depression.
It is well-known that quality of life is reduced by
both chronic illnesses16 and anxiety- or mood dis-
orders.17 Asthma, as a chronic disease, has been shown to
reduce quality of life in general,18 with higher levels
of severity leading to greater decrements in quality of
life.19 Compromised mental health has been shown to
reduce quality of life in asthmatics,20 and specifi-
cally anxiety and depression have additional negative
effects.9,13,21
In sum, there is evidence that both anxiety and depres-
sion affect health care use, medication treatment, and
quality of life in asthma. The literature on effects of anxiety
is particularly strong, and together with the heightened
prevalence rates of anxiety disorders, in particular panic
disorder, suggests an important role of this aspect of
psychopathology in asthma. The literature on the effects
of depression, on the other hand, is less substantial.
In addition, most studies have not addressed the typi-
cally moderate to high correlation between anxiety and
depression psychopathology. It is possible that most asso-
ciations with health care use, treatment, and quality
of life are accounted for by anxiety alone, and that
depression would contribute little effects. Thus, we sought
to explore in a cross-sectional study the extent to
which both anxiety and depression are associated withhealth care use and quality of life in asthmatic patients,
after controlling for demographic factors and symptoms as
indicators of severity of disease, and whether depression




Data for these analyses were collected during pre-tests at
the Pulmonary Research Institute at Hospital Grosshansdorf
within larger studies (e.g. BIOAIR) approved by the local
ethics committee. None of the participants was enrolled in
an intervention study while taking part in our questionnaire
survey. Data collection was completely blinded and patients
returned their questionnaires anonymously in a sealed
envelope.
Instruments
Patients filled in an ad hoc questionnaire on demographic
and general asthmatic information. This included informa-
tion on asthma history and symptoms, treatment of their
disease, and health care use. We inquired about the number
of primary care visits in the previous year (i.e., ‘‘How many
times in the last year did you see your general practitioner
or specialist for your asthma?’’) and life-time hospital
visits (i.e., ‘‘How often have you been treated in a hospital
due to your asthma?—in your whole life?’’). In addition,
patients were asked about the number of days on oral
corticosteroids in the previous year (i.e., ‘‘For how long did
you take steroid tablets for your asthma in the last year
(no inhaler, turbo-haler)?’’). To determine asthma symptom
severity, patients were asked about frequency of symptoms
per week (question: ‘‘How often did you have breath-
ing problems or asthma symptoms during the last 14 days?’’,
answers: ‘‘never—up to two times a week—more than
two times a week, but less than one time a day—
daily symptoms—continual symptoms’’), symptoms per
night (question: ‘‘Do you have any asthma symptoms at all
during the night?’’, answers: ‘‘never—up to two times
a month—more than two times a month, but less-than
one time a week—more than one time a week—almost
every night’’), and restrictions in daily activity due to
asthma (question: ‘‘How often did these symptoms
affect your daily activities during the last two weeks?’’,
answers: ‘‘never—less than two times a week—up to two
times a week—more than two times a week, but less
than one time a day—daily—continuously’’), following
standards developed in the Global Initiative for Asthma
(GINA).22
For psychological status, the 14-item Hospital Anxiety and
Depression Scale (HADS)23 was used, which is ideally suited
for clinical settings because items avoid any reference to
physical symptoms. Seven questions relate to anxiety and
seven to depression, with total scores for both subscales in
the range of 0–21. A value of 7 or less was interpreted as
non-clinical, 8–10 as indicating possible clinical relevance,
and values of 11 or higher as indicating important
relevance.24
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Questionnaire (SF-12)25 was used, which is a brief, reliable
measure of general health status. The 12 items measure
physical functioning as well as role limitation due to physical
and emotional health problems, and it allows for the
calculation of two summary scores, physical well-being
and mental well-being.
Asthma-specific quality of life was measured with the
revised questionnaire ‘‘Fragebogen zur Lebensqualitaet
bei Asthma’’,26 a German version of the Living with
Asthma Questionnaire (LAQ),27 with a total of 40 items.
Participants rated on a three-point scale their subjective
experiences with asthma, including both functional limita-
tion and distress. The German version yields three major
dimensions: physical criteria (asthma symptoms, physical
percepts), mental stress, and functional status (daily
activities, job-related capacity); a total score can also be
calculated.Data analysis
To test the hypotheses that a relationship between depres-
sion and both health care use and quality of life in patients
with asthma exists after controlling for demographics,
symptom severity, and anxiety, we calculated a series of
hierarchical multiple regression analyses. Data from
these regression analyses with significant results in more
than one of the assumed predictors are presented. In
each equation demographic variables (age, gender, level
of education) were entered in the first step, symptom
severity of asthma (described by frequency of symptoms
per week, symptoms per night, and restrictions in daily
activity due to asthma) in the second step, the HADS
anxiety score in the third step, and the HADS depression
score in the forth step. Health care use variables were
log-transformed before entering the analysis. The assump-
tion of normal distribution of the residuals was confirmed
using the Kolmogorov–Smirnov-test (skewnesso1) for
each multiple linear regression analysis. We also ensured
that criteria for extreme outliers (Cook’s Distance41.0)
and multicollinearity (variance inflation factors44) were




Education, A-levels or degree (%)
Marriage status: married/cohabiting (%)
Age at asthma onset (years)
Duration of asthma
Seasonal symptoms, spring/summer (%)
Smoking, current smoker (%)
Asthma-related GP visits, previous year (median, percentiles)
Hospitalization, lifetime (median, percentiles)




Ninety-one patients with a diagnosis of bronchial asthma
were recruited, with 88 of these returning completed
anxiety and depression questionnaire data. Participants of
the study were both out-patients as well as in-patients (83%
vs. 17%), either admitted for treatment of acute exacerba-
tion or reassessment of asthma management. Demographics
and disease characteristics of the sample are presented in
Table 1. Asthma severity ratings according to GINA-guide-
lines 22 regarding current medication treatment were
categorized as Step 1 (intermittent asthma) for 18% of the
sample, Step 2 (mild persistent asthma) 22%, Step 3
(moderate persistent asthma) 49%, and Step 4 (severe
persistent asthma) 11% (all on daily oral steroids). Daily or
permanent symptoms were reported by 39%. Nighttime
symptoms were reported by 55%, with 13% not being able to
sleep through most of the night. Daily or permanent
restrictions in daily activities were described by 17% of the
patients. The average duration of the disease was 24 years
(range: 4–63 years), with onset before the age of 18 years in
37% of the sample. A family history of asthma and/or
allergies was reported by 57%. Skin tests for allergies were
positive in most cases (81%), including pollen (66%), house
dust (54%), animal hair (41%), molds (10%), and others (e.g.
drugs, metals, food; 16%). For the HADS questionnaire 10
patients (11%) had clinically significant levels (values of 11
or higher) of anxiety and eight (9%) depression; clinically
significant scores on both scales were found in five patients
(6%). The Pearson correlation between the subscales HADS-A
and HADS-D was significant (rð88Þ ¼ :689, Po.001).
Associations between depression and health care
use
In these hierarchical multiple regression analyses we used
the following dependent variables: (1) primary care visits
during the last year; (2) hospital visits for the whole life; and
(3) oral steroid-intake in the last year. Controlling for
demographics and symptom severity, anxiety was notns for asthma patients (N ¼ 88).















Table 2 Associations of anxiety and depression (after controlling for anxiety) with health care use (N ¼ 88).a
B SE b R2 DR2 P
Criterion: Primary care (last year)
Symptom severity —b — — .282 .165 .001
Anxiety .005 .009 .066 .286 .003 .573
Depression .021 .012 .273 .316 .030 .075
Criterion: Hospital visits (lifetime)
Symptom severity — — — .184 .056 .164
Anxiety .011 .011 .121 .195 .010 .331
Depression .034 .014 .383 .254 .059 .018
Criterion: Oral steroids (last year)
Symptom severity — — — .358 .150 .001
Anxiety .017 .020 .096 .365 .006 .386
Depression .077 .077 .435 .441 .076 .002
aResults from hierarchical multiple linear regressions analysis controlling for gender, age, and education level in step 1, and symptom
severity (weekly symptom frequency, nighttime symptoms, daily activity restrictions) in step 2.
bFor brevity, regression coefficients are only reported for step 3 (anxiety) and step 4 (depression); full results can be obtained by the
authors upon request.
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higher depression scores were significantly related to more
hospital visits, after controlling for demographics, symptom
severity, and anxiety. Elevated depression scores, but not
anxiety scores, were also significantly associated with the
number of days on oral steroids in the previous year. Without
controlling for anxiety, depression scores were no longer
significantly related to hospital visits. Symptom severity
accounted significantly for 15% and 17% of the variance in
primary care visits and oral corticosteroids, respectively. On
the other hand, symptom severity accounted for no
significant variance in hospital visits.Associations between depression and both general
and asthma-specific quality of life
In separate regression analyses, we tested the associations
between HADS depression scores and the general and the
asthma-specific quality of life questionnaires. Dependent
variables in these analyses were the scores of the SF-12
subscales physical- and mental well-being and both the sum-
score of the LAQ and the scores of the subscales physical,
psychological, and functional well-being, respectively.
Associations with the subscales of the SF-12 and the LAQ
yielded a comparable pattern of results (Table 3). After
controlling for demographics and symptom severity, anxiety
accounted for considerable variance in SF-12 mental well-
being and LAQ psychological well-being. Including depres-
sion in a third step accounted for additional variance in
these subscales (SF-12 mental well-being and LAQ psycho-
logical well-being). For physical well-being, we found
significant associations with depression, but not with
anxiety. Considerable associations were also found between
anxiety as well as depression and the LAQ functional
subscale and the sum-score of the LAQ (4% and 3%,
respectively). Symptom severity accounted for sizeableportions of the variance in physical and mental aspects of
quality of life.
Without controlling for anxiety, the significance of the
associations of depression scores with sum-score and scores
of the subscale of the LAQ increased slightly (absolute
values: 10% for psychological, 2% for physical, 8% for
functional, 7% for general), and with the SF-12 they
increased for mental well-being (28%) and decreased for
physical well-being (5%).Discussion
In this study we examined the influence of depression on
health care use and quality of life in asthma. Previous
studies had shown that depression was associated with
several aspects of health care use and quality of life, but
none had controlled for comorbid anxiety. Given the
typically substantial comorbidity between anxiety and
affective disorders and substantial correlations between
psychological measures of both problem areas,29 we were
able to show that even if effects for anxiety were controlled
for, depressive characteristics still predicted a small portion
of the variance in health care use, and considerable
variance in quality of life of asthma patients. This partly
confirmed earlier findings of an association between
elevated levels of depression and hospitalization,14,15 more
corticosteroid intake,13 and decreased quality of life.21 We
extended these findings by showing that parts of these
associations are unique to depression and were not
exclusively, or not at all, explained by greater levels of
anxiety or symptom severity. Interestingly, we were not able
to confirm the relationship between anxiety and health care
use9,10 or oral corticosteroid use.11,12 Part of this discre-
pancy may be due to differences in samples and measures
used. It may also be that the association between these
variables and anxiety is mediated through self-reported
symptom severity, and by controlling for it the importance
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Table 3 Associations of anxiety and depression (after controlling for anxiety) with general and asthma-specific quality of life
(N ¼ 88).a
B SE b R2 DR2 P
Criterion: SF-12, physical well-being
Symptom severity —b — — .501 .224 .000
Anxiety .062c .097 .062 .504 .003 .525
Depression .384c .121 .384c .563 .060 .002
Criterion: SF-12, mental well-being
Symptom severity — — — .249 .127 .008
Anxiety .664 .119 .560 .470 .221 .000
Depression .551 .144 .465 .558 .087 .000
Criterion: LAQ, physical
Symptom severity — — — .643 .309 .000
Anxiety .171 .204 .069 .647 .003 .404
Depression .546 .263 .219 .666 .019 .041
Criterion: LAQ, psychological
Symptom severity — — — .506 .282 .000
Anxiety .732 .174 .365 .600 .094 .000
Depression .515 .224 .257 .627 .027 .024
Criterion: LAQ, functional
Symptom severity — — — .565 .282 .000
Anxiety .541 .182 .255 .611 .046 .004
Depression .621 .231 .293 .646 .035 .009
aResults from hierarchical multiple linear regressions analysis controlling for gender, age, and education level in step 1, and symptom
severity (weekly symptom frequency, night time symptoms, daily activity restrictions) in step 2.
bFor brevity, regression coefficients are only reported for step 3 (anxiety) and step 4 (depression); full results can be obtained by the
authors upon request.
cValues for B and b are similar because the standard deviation of the dependent variable (physical well-being) and the independent
variable (anxiety and depression, respectively) are almost identical.
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study. With regard to the depression scale, controlling for
both symptom report and anxiety also guaranteed that
reports of greater health care or medication use and lower
quality of life were less likely to reflect a general complaint
tendency in patients.
Our findings indicate that anxiety and depression probably
play a smaller role with respect to utilization of health care
(with a maximum of 6% variance explained), but their role is
more significant with respect to perceived quality of life of
the patients. Anxiety alone accounted significantly only for
variance the mental well-being score on both generic and
asthma-specific measures. Depression on the other hand was
also related to decreased physical well-being, even after
controlling for anxiety. Thus, depressive symptoms seem to
have more far-reaching implications for the asthma disease
process and/or management outcome than anxiety symp-
toms. Indeed, depression has frequently been identified as a
problematic psychopathological feature in the treatment of
asthma. In childhood, depression has been linked to life-
threatening or fatal asthma.30 However, the mechanisms of
the association between depression and reduced asthma-
specific quality of life remain to be elucidated. Both direct
pathways through asthma self-management and direct
biological pathways have been proposed.31 Depression may
also directly impact the pathophysiological process, throughincreases in vagally induced bronchoconstriction or influ-
ences on immune function. It has been hypothesized that
the cholinergic pathway is responsible for depression-
induced asthma exacerbations in children.32 Experimental
studies of emotion induction have demonstrated that
specifically in depressive states, airway obstruction is
associated with vagal excitation.3,33 Alternatively, dysregu-
lation of neuroendocrine and immune pathways by depres-
sion have been considered in asthma.34 Down-regulation of
the hypothalamic–pituitary–adrenal axis35 is capable of
exacerbating inflammatory processes, and stress-induced
catecholamine release could be involved in alterations of
the cytokine profile, favoring allergic inflammation.36
Finally, with respect to the observed positive association
between depression and oral corticosteroid intake, a
reverse causation should also be considered. Elevated levels
of depression could also be a psychological side effect of
high corticosteroid medication doses.13,37
The findings of this study should be considered within
the context of some methodological limitations. First,
the sample was drawn from only one hospital specialized
in the treatment of respiratory diseases. Patients were
largely in the age group between 54 and 66 years (52%),
had mostly moderate to severe asthma, and reported
allergies, thus possibly limiting the generalizability of our
findings for younger and milder cases of asthma. Second,
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which allow no direct inference regarding actual diagnosis
through psychiatric interview.38 However, the instruments
used in the present study (HADS, SF-12, LAQ) have been
shown to be valid evaluation tools with excellent measure-
ment properties. The advantage of the dimensional
approach using the HADS is that it helps uncover a
continuum of potentially problematic psychological features
that also include sub-clinical cases. Third, in this study we
determined asthma severity mainly through symptoms and
treatment, and no measures of lung function or other
diagnostic tests were collected. However, all patients were
currently being treated for their disease and their asthma
diagnosis had been confirmed previously by respiratory
specialists. For the regression analyses we used self-
reported symptom severity as a proxy of asthma severity,
which we expected to be more closely related to health care
use and current quality of life. Fourth and finally, the study
is limited by its cross-sectional nature. Thus, at this point we
cannot determine whether depression causes decrements in
asthma-specific quality of life or whether the actual
decrements in asthma-specific quality of life lead to
depression in patients. Future longitudinal studies may be
able to address these issues successfully, and may also
uncover mediators or moderators of the relationship
between depression and health care use or quality of life
in asthma.
The results of this study highlight the importance of
depression in asthma management. Even after controlling
for symptom severity and anxiety, depression is associated
with a decrease in general and asthma-specific quality of
life, greater intake of corticosteroids, and marginally
increased hospitalization. An implementation of routine
screening for depression in hospital and primary care asthma
patients should be considered in order to inform health care
personnel better about patients in need for adjunctive
behavioral therapy or psychiatric intervention. Future
studies should explore longitudinal associations between
depression, health care use, and quality of life, and factors
mediating their association.
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